CN102846605B - Medicinal composition, as well as preparation process and application thereof - Google Patents
Medicinal composition, as well as preparation process and application thereof Download PDFInfo
- Publication number
- CN102846605B CN102846605B CN201210274070.7A CN201210274070A CN102846605B CN 102846605 B CN102846605 B CN 102846605B CN 201210274070 A CN201210274070 A CN 201210274070A CN 102846605 B CN102846605 B CN 102846605B
- Authority
- CN
- China
- Prior art keywords
- amoxicillin
- weight portion
- anhydrous glucose
- soluble powder
- ambroxol hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal composition, which comprises the following components in parts by weight: 5 to 15 parts of amoxicillin, 1 to 5 parts of clavulanate potassium, and 1 to 5 parts of ambroxol hydrochloride. The invention discloses an application of the medicinal composition in preparing medicaments for treating animal respiratory infectious diseases, in particular for preparing porcine infectious pleuropneumonia and haemophilusparasuis. The invention also discloses a preparation method of compound amoxicillin soluble powder. The compound amoxicillin soluble powder comprises the following components in parts by weight: 5 to 15 parts of amoxicillin, 1 to 5 parts of clavulanate potassium, 1 to 5 parts of ambroxol hydrochloride, and 75 to 93 parts of glucosum anhydricum. The raw materials are uniformly mixed according to an equivalent incremental principle to obtain the compound amoxicillin soluble powder. The medicinal composition disclosed by the invention is reasonable and scientific in prescription, the bioavailability of amoxicillin can be increased compared with an amoxicillin preparation, the drug resistance is reduced, and the curative effect is improved.
Description
Technical field
The invention belongs to animal health and field of veterinary, be specifically related to a kind of pharmaceutical composition containing amoxicillin and preparation technology thereof and application.
Background technology
Antibiotic, at Animal diseases prevention and a large amount of not scientifical use in therapeutic process, result in the sensitivity of antibacterial to common antibiotics more and more lower.Antibacterial then produces drug resistance by number of ways to antibiotic, and wherein to produce beta-lactamase, the beta-lactam nucleus in hydrolyzing penicillin, cephalosporins medicine etc. is main.Use beta-lactamase inhibitor greatly can improve the antibacterial activity of some beta-lactam antibiotic, and expand antimicrobial spectrum.
Wang Hongning teaches between 1999 to 2011; find in the bacterial drug resistance of western China large-scale pig farm is detected, antibacterial to the average resistant rate of Tetracyclines, penicillins, Macrolide, fluoroquinolones, chloromycetin medicine up to 91%, 85.8%, 83.8%, 54.15%, 51.8%
Amoxicillin, i.e. amoxycillin XiLin, be a kind of the most frequently used penicillins beta-lactam broad ectrum antibiotic, be white powder, the half-life is about 61.3min.Amoxicillin is stablized in acid condition, and gastrointestinal absorption rate reaches 90%, and its bactericidal action is strong, and energy is permeates cell membranes rapidly, is one of optimal drug being used for the treatment of animal breath systemic disease, pig hemophilus disease and puerperal infection at present.But amoxicillin is easily subject to the attack of beta-lactamase in body and is hydrolyzed, the effective blood drug concentration of amoxicillin reduces, and causes the drug resistance of various antibacterial to amoxicillin constantly to increase.Therefore, alone amoxicillin does not more and more reach expected effect to the various disease for the treatment of.
Clavulanate potassium is beta-lactamase inhibitor, and can be combined with beta-lactamase and generate irreversible conjugate, antibacterial activity own is more weak.Clavulanate potassium coordinates amoxicillin can significantly improve the antibacterial activity of amoxicillin and the penetration capacity of cell membrane thereof, and curative effect can increase several times even tens times, and Resistant strain can be made to recover responsive to medicine.
Ambroxol is current the most widely used expectorant clinically, the formation of respiratory tract interfacial agent can be stimulated and regulate serosity and mucous secretion, the eliminating effect in respiratory tract cilium district and fibre-less district can be improved simultaneously, reduce the adhesion strength of sputum and cilium, make the easy expectoration of expectorant further, and alleviate the phenomenon of cough.But itself does not have antibacterial action.Inventor is found by research, and ambroxol and amoxicillin, clavulanate potassium coupling, can improve the concentration of amoxicillin in bronchus and lung tissue, raising antibacterial effect.But there is not yet the report of the compound preparation about triple combination so far.
Summary of the invention
The object of the invention is for above-mentioned technical problem, provide a kind of antibacterial effect better, use amoxicillin compound preparation more easily; Described amoxicillin compound preparation is to animal breath systematic infection disease, and the therapeutic effect as porcine contagious pleuropneumonia, Haemophilus parasuis is obviously better than amoxicillin single preparations of ephedrine; And described compound preparation formula is reasonable, science, compares, improves the bioavailability of amoxicillin, decrease its consumption with the single preparations of ephedrine of amoxicillin, safer.
In order to achieve the above object, the present invention adopts following technical scheme:
A kind of pharmaceutical composition, comprises the component of following weight portion:
Amoxicillin 5-15 weight portion, clavulanate potassium 1-5 weight portion, ambroxol hydrochloride 1-5 weight portion.
Pharmaceutical composition of the present invention, also comprises pharmaceutically acceptable adjuvant 75-93 weight portion.The preferred anhydrous glucose of described pharmaceutically acceptable adjuvant.
As a preferred embodiment of the present invention, described pharmaceutical composition comprises the component of following weight portion:
Amoxicillin 10 weight portion, clavulanate potassium 2.5 weight portion, ambroxol hydrochloride 2 weight portion.
Above-mentioned pharmaceutical composition, also comprises pharmaceutically acceptable adjuvant 85.5 weight portion.The preferred anhydrous glucose of described pharmaceutically acceptable adjuvant.
Another object of the present invention is to provide aforementioned pharmaceutical compositions, the application in the medicine of preparation treatment animal respiratory infectious disease.
Described animal respiratory infectious disease comprises porcine contagious pleuropneumonia and Haemophilus parasuis.
The present invention also provides a kind of preparation method of compound amoxicillin soluble powder, and described compound amoxicillin soluble powder is made up of following component:
Amoxicillin 5-15 weight portion, clavulanate potassium 1-5 weight portion, ambroxol hydrochloride 1-5 weight portion, anhydrous glucose 75-93 weight portion.
Preferably being configured to of said components:
Amoxicillin 10 weight portion, clavulanate potassium 2.5 weight portion, ambroxol hydrochloride 2 weight portion, anhydrous glucose 85.5 weight portion.
The preparation method of described compound amoxicillin soluble powder comprises the steps:
(1) amoxicillin of described weight portion, clavulanate potassium, ambroxol hydrochloride and anhydrous glucose are sieved for subsequent use respectively;
(2) take cross be sieved the amoxicillin of described weight portion, clavulanate potassium, ambroxol hydrochloride and about weight portion described in 1/3rd anhydrous glucose to progressively increase the abundant mix homogeneously of principle according to equivalent, obtain mixture 1;
(3) anhydrous glucose again residue having been crossed good sieve joins in described mixture 1, and abundant mix homogeneously, discharging, sieves, and to obtain final product.
Pharmaceutical composition of the present invention, can by various ways administrations such as oral, non-bowel, suction-type sprayings, preferably oral administration.Pharmaceutical composition for oral use, can be any one acceptable preparation, include but not limited to: soluble powder, aqueous solution, tablet, capsule etc., preferably soluble powder.Medicinal composition for oral administration, the pharmaceutically acceptable adjuvant that can select, comprises anhydrous glucose, soluble starch, lactose etc., preferably anhydrous glucose.
Pharmaceutical composition of the present invention, amoxicillin is beta-lactam antimicrobial drug, and clavulanate potassium is beta-lactamase inhibitor, and ambroxol hydrochloride is pulmonary's precursor priming; Three's rational proportion, makes described pharmaceutical composition have triple function:
1, clavulanate potassium suppresses the beta-lactamase that drug-resistant bacteria produces, and reduces drug-resistant bacteria to the decomposition of amoxicillin, makes the sensitivity of fastbacteria recovery to amoxicillin; Improve simultaneously and maintain the blood drug level of amoxicillin; Thus improve the curative effect of described compositions;
2, ambroxol hydrochloride makes amoxicillin in pulmonary's enrichment, improves the effect that amoxicillin is treated pulmonary disease;
3, ambroxol hydrochloride rapid recovery animal, as the dyspnea that pig too much causes because of sputum, promotes body recovery;
Pharmaceutical composition of the present invention, compared with the single preparations of ephedrine of amoxicillin, therapeutic effect is better, takes effect faster; The medication of raiser's blindness can be avoided to cause abuse of antibiotics and drug waste simultaneously.
Compound amoxicillin soluble powder of the present invention is easy to use.After oral administration, through medicine generation dynamic learning investigate, the amoxicillin half-life comparatively amoxicillin single preparations of ephedrine extend, effective blood drug concentration is held time length.
The pharmacokinetics comparative study of medicinal composition of the present invention and amoxicillin single preparations of ephedrine:
Test animal: the health pig of 30 ages in days
Test medicine: 1) 10% compound amoxicillin soluble powder
Take amoxicillin 10kg, clavulanate potassium 2.5kg, ambroxol hydrochloride 2kg and anhydrous glucose 85.5kg, sieve for subsequent use respectively.Amoxicillin 10kg and anhydrous glucose 10kg are added small-sized V-Mixer mixing 5min, continues to add anhydrous glucose 20kg mixing 5min and obtain A material; Clavulanate potassium 2.5kg and anhydrous glucose 2.5kg are added small-sized V-Mixer mixing 5min to obtain B and expect; Ambroxol hydrochloride 2kg and anhydrous glucose 2kg are added small-sized V-Mixer mixing 5min to obtain C and expect, A, B, C three is added larger V-Mixer mixing 20min, obtain mixture 1; Residue anhydrous glucose 51kg is added in described mixture 1, in two-dimensional mixing machine, fully mix 30 minutes, to obtain final product.
2) 10% amoxicillin soluble powder
Amoxicillin 10kg is mixed homogeneously with anhydrous glucose 90kg, to obtain final product.
Test method: 40 30 age in days health pig are divided into 4 groups at random, at fasting one night before experiment, then, take orally to respectively described 10% compound amoxicillin soluble powder spice for 1,2 group, the every 100kg feedstuff of pig adds this product 50g.3, take orally to respectively described 10% amoxicillin soluble powder spice for 4 groups, the every 100kg feedstuff of pig adds this product 50g.Respectively get pig ear vein blood about 4 ml in 0.25,0.5,1.0,1.5,2.0,3.0,4.0,5.0,7.0 h after administration, put in test tube, blood sample uses high performance liquid chromatography (HPLC) method to detect the concentration of wherein amoxicillin after treatment.
Result of the test: the blood concentration-time curve of described 10% compound amoxicillin soluble powder and 10% amoxicillin soluble powder is shown in attached Fig. 1 and 2 respectively.The main medicine of described 10% compound amoxicillin soluble powder is in parameter, the time (Tmax) that amoxicillin reaches maximum plasma concentration in pig body is 2.0h, peak concentration of drug (Cmax) is 11.2-12.8 μ g/ml, and the half-life (T1/2) of medicine is 1.4h.The main medicine of described 10% amoxicillin soluble powder is in parameter, and the time (Tmax) that amoxicillin reaches maximum plasma concentration in pig body is 1.2h, and peak concentration of drug (Cmax) is 7.9-9.1 μ g/ml, and the half-life (T1/2) of medicine is 0.92h.
Conclusion (of pressure testing): experiment results proved, compared with the single preparations of ephedrine of amoxicillin, compound amoxicillin soluble powder extends the half-life of amoxicillin, makes effective blood drug concentration maintain the longer time.
The preparation method technique of animal compound amoxicillin soluble powder of the present invention is simple, easily realizes.
Accompanying drawing explanation
Fig. 1 is the blood concentration-time curve of 10% compound amoxicillin soluble powder.
Fig. 2 is the blood concentration-time curve of 10% amoxicillin soluble powder.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is elaborated.
Embodiment 1 5% compound amoxicillin soluble powder I
(1) take amoxicillin 5kg, clavulanate potassium 5kg, ambroxol hydrochloride 5kg and anhydrous glucose 85kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin be sieved and in V-Mixer, fully mix 20 minutes with clavulanate potassium, get the ambroxol hydrochloride be sieved and add in said mixture and fully mix 20 minutes in V-Mixer.
(3) joined by the anhydrous glucose be sieved in the mixture of above-mentioned amoxicillin, clavulanate potassium and ambroxol hydrochloride again, fully mixing 30 minutes in two-dimensional mixing machine, discharging, subpackage, obtains described 5% compound amoxicillin soluble powder.
Embodiment 2 5% compound amoxicillin soluble powder II
(1) take amoxicillin 5kg, clavulanate potassium 1kg, ambroxol hydrochloride 1kg and anhydrous glucose 93kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin 5kg be sieved and add small-sized V-Mixer mixing 5min with anhydrous glucose 5kg, continue to add anhydrous glucose 10kg mixing 5min and obtain A material; Clavulanate potassium 1kg and anhydrous glucose 1kg are added small-sized V-Mixer mixing 5min to obtain B and expect; Ambroxol hydrochloride 1kg and anhydrous glucose 1kg are added small-sized V-Mixer mixing 5min to obtain C and expect, A, B, C three is added larger V-Mixer mixing 20min, obtain mixture 1;
(3) join in said mixture 1 by the remaining anhydrous glucose be sieved again, in larger V-Mixer, fully mix 30 minutes, discharging, subpackage, obtains described 5% compound amoxicillin soluble powder II.
Embodiment 3 5% compound amoxicillin soluble powder III
(1) take amoxicillin 5kg, clavulanate potassium 5kg, ambroxol hydrochloride 1kg and corn starch 89kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin be sieved and in V-Mixer, fully mix 20 minutes with clavulanate potassium, get the ambroxol hydrochloride be sieved and add in said mixture and fully mix 20 minutes in V-Mixer.
(3) joined by the corn starch be sieved in the mixture of above-mentioned amoxicillin, clavulanate potassium and ambroxol hydrochloride again, fully mixing 30 minutes in two-dimensional mixing machine, discharging, subpackage, obtains described 5% compound amoxicillin soluble powder III.
Embodiment 4 5% compound amoxicillin soluble powder IV
(1) take amoxicillin 5kg, clavulanate potassium 1kg, ambroxol hydrochloride 5kg and anhydrous glucose 89kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin 5kg be sieved and add small-sized V-Mixer mixing 5min with anhydrous glucose 5kg, continue to add anhydrous glucose 10kg mixing 5min and obtain A material; Clavulanate potassium 1kg and anhydrous glucose 1kg are added small-sized V-Mixer mixing 5min to obtain B and expect; Ambroxol hydrochloride 5kg and anhydrous glucose 5kg are added small-sized V-Mixer mixing 5min to obtain C and expect, A, B, C three is added larger V-Mixer mixing 20min, obtain mixture 1;
(3) join in said mixture 1 by the remaining anhydrous glucose be sieved again, in larger V-Mixer, fully mix 30 minutes, discharging, subpackage, obtains 5% compound amoxicillin soluble powder IV.
Embodiment 5 10% compound amoxicillin soluble powder I
(1) take amoxicillin 10kg, clavulanate potassium 5kg, ambroxol hydrochloride 5kg and anhydrous glucose 80kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin 10kg be sieved and add small-sized V-Mixer mixing 5min with anhydrous glucose 10kg, continue to add anhydrous glucose 20kg mixing 5min and obtain A material; Clavulanate potassium 5kg and anhydrous glucose 5kg are added small-sized V-Mixer mixing 5min to obtain B and expect; Ambroxol hydrochloride 5kg and anhydrous glucose 5kg are added small-sized V-Mixer mixing 5min to obtain C and expect, A, B, C three is added larger V-Mixer mixing 20min, obtain mixture 1;
(3) join in said mixture 1 by the remaining anhydrous glucose be sieved again, in larger V-Mixer, fully mix 30 minutes, discharging, subpackage, obtains 10% compound amoxicillin soluble powder I.
Embodiment 6 10% compound amoxicillin soluble powder II
(1) take amoxicillin 10kg, clavulanate potassium 5kg, ambroxol hydrochloride 1kg and corn starch 84kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin be sieved and in V-Mixer, fully mix 20 minutes with clavulanate potassium, get the ambroxol hydrochloride be sieved and add in said mixture and fully mix 20 minutes in V-Mixer.
(3) joined by the corn starch be sieved in the mixture of above-mentioned amoxicillin, clavulanate potassium and ambroxol hydrochloride again, fully mixing 30 minutes in two-dimensional mixing machine, discharging, subpackage, obtains 10% compound amoxicillin soluble powder II.
Embodiment 7 10% compound amoxicillin soluble powder III
(1) take amoxicillin 10kg, clavulanate potassium 1kg, ambroxol hydrochloride 5kg and anhydrous glucose 84kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin be sieved and in V-Mixer, fully mix 20 minutes with clavulanate potassium, get the ambroxol hydrochloride be sieved and add in said mixture and fully mix 20 minutes in V-Mixer.
(3) joined by the anhydrous glucose be sieved in the mixture of above-mentioned amoxicillin, clavulanate potassium and ambroxol hydrochloride again, fully mixing 30 minutes in two-dimensional mixing machine, discharging, subpackage, obtains 10% compound amoxicillin soluble powder III.
Embodiment 8 10% compound amoxicillin soluble powder IV
(1) take amoxicillin 10kg, clavulanate potassium 1kg, ambroxol hydrochloride 1kg and anhydrous glucose 88kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin 10kg be sieved and add small-sized V-Mixer mixing 5min with anhydrous glucose 10kg, continue to add anhydrous glucose 20kg mixing 5min and obtain A material; Clavulanate potassium 1kg and anhydrous glucose 1kg are added small-sized V-Mixer mixing 5min to obtain B and expect; Ambroxol hydrochloride 1kg and anhydrous glucose 1kg are added small-sized V-Mixer mixing 5min to obtain C and expect, A, B, C three is added larger V-Mixer mixing 20min, obtain mixture 1;
(3) join in said mixture 1 by the remaining anhydrous glucose be sieved again, in larger V-Mixer, fully mix 30 minutes, discharging, subpackage, obtains 10% compound amoxicillin soluble powder IV.
Embodiment 9 5% compound amoxicillin soluble powder V
(1) take amoxicillin 5kg, clavulanate potassium 2kg, ambroxol hydrochloride 2kg and anhydrous glucose 91kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin be sieved and in V-Mixer, fully mix 20 minutes with clavulanate potassium, get the ambroxol hydrochloride be sieved and add in said mixture and fully mix 20 minutes in V-Mixer.
(3) joined by the anhydrous glucose be sieved in the mixture of above-mentioned amoxicillin, clavulanate potassium and ambroxol hydrochloride again, fully mixing 30 minutes in two-dimensional mixing machine, discharging, subpackage, obtains 5% compound amoxicillin soluble powder V.
Embodiment 10 5% compound amoxicillin soluble powder VI
(1) take amoxicillin 5kg, clavulanate potassium 2.5kg, ambroxol hydrochloride 2kg and anhydrous glucose 90.5kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin 5kg be sieved and add small-sized V-Mixer mixing 5min with anhydrous glucose 5kg, continue to add anhydrous glucose 10kg mixing 5min and obtain A material; Clavulanate potassium 2.5kg and anhydrous glucose 2.5kg are added small-sized V-Mixer mixing 5min to obtain B and expect; Ambroxol hydrochloride 2kg and anhydrous glucose 2kg are added small-sized V-Mixer mixing 5min to obtain C and expect, A, B, C three is added larger V-Mixer mixing 20min, obtain mixture 1;
(3) join in said mixture 1 by the remaining anhydrous glucose be sieved again, in two-dimensional mixing machine, fully mix 30 minutes, discharging, subpackage, obtains compound amoxicillin soluble powder of the present invention.
Embodiment 11 10% compound amoxicillin soluble powder V
(1) take amoxicillin 10kg, clavulanate potassium 4kg, ambroxol hydrochloride 2kg and anhydrous glucose 84kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin be sieved and in V-Mixer, fully mix 20 minutes with clavulanate potassium, get the ambroxol hydrochloride be sieved and add in said mixture and fully mix 20 minutes in V-Mixer.
(3) joined by the anhydrous glucose be sieved in the mixture of above-mentioned amoxicillin, clavulanate potassium and ambroxol hydrochloride again, fully mixing 30 minutes in two-dimensional mixing machine, discharging, subpackage, obtains 10% compound amoxicillin soluble powder V.
Embodiment 12 10% compound amoxicillin soluble powder VI
(1) take amoxicillin 10kg, clavulanate potassium 2.5kg, ambroxol hydrochloride 2kg and anhydrous glucose 85.5kg, cross 80 mesh sieves respectively, for subsequent use.
(2) get the amoxicillin 10kg be sieved and add small-sized V-Mixer mixing 5min with anhydrous glucose 10kg, continue to add anhydrous glucose 20kg mixing 5min and obtain A material; Clavulanate potassium 2.5kg and anhydrous glucose 2.5kg are added small-sized V-Mixer mixing 5min to obtain B and expect; Ambroxol hydrochloride 2kg and anhydrous glucose 2kg are added small-sized V-Mixer mixing 5min to obtain C and expect, A, B, C three is added larger V-Mixer mixing 20min, obtain mixture 1;
(3) join in said mixture 1 by the remaining anhydrous glucose be sieved again, in larger V-Mixer, fully mix 30 minutes, discharging, subpackage, obtains 10% compound amoxicillin soluble powder VI.
comparative example:
By following animal effect experiment, the curative effect of amoxicillin of the present invention is described
1. animal subject:
Random selecting have asthma, cough, ventral breathing symptom and autologous in from the piglet 150 going out Actinobacillus pleuropneumoniae, haemophilus parasuis, body weight is at 30 ~ 50kg.
2. test medicine
1) 10% compound amoxicillin soluble powder VI of the embodiment of the present invention 12 preparation;
2) 10% amoxicillin soluble powder: is mixed homogeneously with 90 powder anhydrous glucose and get final product in 10 parts, amoxicillin;
3) anhydrous grape Icing Sugar (Jiangxi Yuan Wang Industrial Co., Ltd.).
3. test method:
150 selected ill pigs are divided into three groups at random by body weight, often organize 50.Grade evaluation is carried out to the order of severity of clinical symptoms.Each group of administering mode and dosage refer to table 1, and successive administration 7 days, records the body weight of every pig last day, and again carry out grade evaluation to the order of severity of clinical symptoms, calculate each group of average weight gain (kg) and cure rate.The results are shown in Table 1.
Table 1
| Group | Animal (head) | Dosage/administering mode | Average weight gain (kg) | Clinical symptoms serious (1d) | The clinical symptoms order of severity (7d) | Cure rate (%) |
| Blank group (anhydrous glucose) | 50 | Spice takes orally, and the every 100kg feedstuff of pig adds this product 50g mixing and uses 7 days continuously | 0.54 | +++ | +++ | 28.7 |
| Compound amoxicillin soluble powder | 50 | Spice takes orally, and the every 100kg feedstuff of pig adds this product 50g mixing and uses 7 days continuously | 1.37 | +++ | - | 76.1 |
| Amoxicillin soluble powder | 50 | Spice takes orally, and the every 100kg feedstuff of pig adds this product 50g mixing and uses 7 days continuously | 1.22 | +++ | + | 62.4 |
note: wherein by the clinical order of severity divide 4 grade evaluations (-for normal ,+for slight, ++ moderate, +++ more serious)
4. result of the test:
Show after this result of the test statistical analysis, compare with matched group, described 10% compound amoxicillin soluble powder VI and 10% amoxicillin soluble powder all can significantly improve cure rate in pole, significantly improve the clinical symptoms order of severity, but at the end for the treatment of, the clinical symptoms of compound amoxicillin soluble powder group all disappears, and cure rate is apparently higher than amoxicillin soluble powder group, and weight average weightening finish is higher than amoxicillin soluble powder group.
5. conclusion (of pressure testing)
Compared with the amoxicillin single preparations of ephedrine of same dosage, the better efficacy of compound amoxicillin soluble powder of the present invention, display clavulanate potassium and ambroxol hydrochloride serve the effect of Synergistic to amoxicillin.
Claims (6)
1. treat a pharmaceutical composition for animal respiratory infectious disease, it is characterized in that: the component comprising following weight portion:
Amoxicillin 10 weight portion, clavulanate potassium 2.5 weight portion, ambroxol hydrochloride 2 weight portion.
2. pharmaceutical composition according to claim 1, is characterized in that: also comprise pharmaceutically acceptable adjuvant 85.5 weight portion.
3. pharmaceutical composition according to claim 2, is characterized in that: described pharmaceutically acceptable adjuvant is anhydrous glucose, lactose, Matrii Sulfas Exsiccatus, soluble starch.
4. the application of the arbitrary described pharmaceutical composition of claims 1 to 3 in the medicine of preparation treatment animal respiratory infectious disease.
5. application according to claim 4, is characterized in that; Described animal respiratory infectious disease is selected from porcine contagious pleuropneumonia, Haemophilus parasuis.
6. a preparation method for compound amoxicillin soluble powder, is characterized in that: the formula of described compound amoxicillin soluble powder consists of:
Amoxicillin 10 weight portion, clavulanate potassium 2.5 weight portion, ambroxol hydrochloride 2 weight portion, anhydrous glucose 85.5 weight portion;
Described preparation method comprises the steps:
(1) amoxicillin of described weight portion, clavulanate potassium, ambroxol hydrochloride and anhydrous glucose are sieved for subsequent use respectively;
(2) take cross be sieved the amoxicillin of described weight portion, clavulanate potassium, weight portion described in ambroxol hydrochloride and 1/3rd anhydrous glucose to progressively increase the abundant mix homogeneously of principle according to equivalent, obtain mixture 1;
(3) join in described mixture 1 by the remaining anhydrous glucose crossing good sieve again, abundant mix homogeneously, discharging, sieves, and to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210274070.7A CN102846605B (en) | 2012-08-03 | 2012-08-03 | Medicinal composition, as well as preparation process and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210274070.7A CN102846605B (en) | 2012-08-03 | 2012-08-03 | Medicinal composition, as well as preparation process and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102846605A CN102846605A (en) | 2013-01-02 |
| CN102846605B true CN102846605B (en) | 2015-03-25 |
Family
ID=47393855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210274070.7A Active CN102846605B (en) | 2012-08-03 | 2012-08-03 | Medicinal composition, as well as preparation process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102846605B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919941A (en) * | 2016-05-17 | 2016-09-07 | 湖南泰谷生物兽药有限公司 | Composition containing amoxicillin and potassium clavulanate, and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129359A (en) * | 2007-07-12 | 2008-02-27 | 颜锵 | Pharmaceutical composition containing amoxicillin, ambroxol and beta lactamase restrainer and uses thereof |
| CN101480382A (en) * | 2008-01-09 | 2009-07-15 | 大百汇生物科技（深圳）有限公司 | Pharmaceutical composition for treating acute and chronic nasal sinusitis and preparation method thereof |
-
2012
- 2012-08-03 CN CN201210274070.7A patent/CN102846605B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129359A (en) * | 2007-07-12 | 2008-02-27 | 颜锵 | Pharmaceutical composition containing amoxicillin, ambroxol and beta lactamase restrainer and uses thereof |
| CN101480382A (en) * | 2008-01-09 | 2009-07-15 | 大百汇生物科技（深圳）有限公司 | Pharmaceutical composition for treating acute and chronic nasal sinusitis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 沐舒坦辅助治疗儿童慢性鼻窦炎的临床研究;高鸿明等;《国际医药卫生导报》;20051231;第11卷(第8期);第72-73页 * |
| 阿莫西林鼻窦滴注治疗儿童鼻窦炎的临床疗效;叶征华;《山东大学耳鼻喉眼学报》;20081231;第22卷(第6期);第529-530页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102846605A (en) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104586774B (en) | A kind of preparation technology of Tilmicosin micropill | |
| CN103768026B (en) | Water-soluble micro-powder containing amoxicillin and preparation method thereof | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN1943675A (en) | Tibetan medicinal composition for expectorant, antitussive, antiasthmatic and its preparation method | |
| CN101496811A (en) | Soluble and stable tilmicosin composition | |
| CN104800167A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN102846605B (en) | Medicinal composition, as well as preparation process and application thereof | |
| CN101612152A (en) | A kind of pharmaceutical composition that contains pidotimod and preparation method thereof | |
| CN114557994B (en) | Application of usnic acid and salt preparation thereof in preparation of anti-chicken coccidiosis medicines or feed additives | |
| CN102872014B (en) | A kind of compound florfenicol composition and preparation technology thereof and application | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN103550226B (en) | Compound sulfamonomethoxine sodium injection as well as preparation method thereof | |
| CN104546950A (en) | Compound endothelium corneum gigeriae galli orally disintegrating tablet for children and preparation method thereof | |
| CN104586875A (en) | Preparation method for compound tilmicosin enteric-coated granules | |
| CN101450065A (en) | Powder for treating livestock and poultry mycoplasma infection | |
| CN102895377B (en) | Pharmaceutical composition for treating livestock respiratory diseases and method for preparing pharmaceutical composition for treating livestock respiratory diseases | |
| CN103169652A (en) | Veterinary alkaline lincomycin injection as well as preparation method and use thereof | |
| CN102370656A (en) | Clarithromycin medicine composition and preparation method thereof | |
| CN106474122B (en) | Pharmaceutical composition of amoxicillin and clavulanate potassium and application thereof | |
| CN106362159A (en) | Molecular skeleton type tilmicosin sustained release preparation and preparation method thereof | |
| CN108653228B (en) | Skeleton type sustained-release doramectin tablet and preparation method thereof | |
| CN104208089A (en) | Gastric floating preparation for treating poultry proventriculitis and preparation method thereof | |
| CN103446171A (en) | Composition for treating swine respiratory tract infection and preparation method thereof | |
| EP3733176A1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof | |
| CN107616977A (en) | A kind of compound preparation for treating antimigraine and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 332000 east of Huanyu high voltage line to the south of Nanwei 1st Road, Gongqingcheng industrial new area, Jiujiang City, Jiangxi Province Patentee after: Jiangxi Dacheng Biotechnology Co., Ltd Address before: 332020 Jiangxi province Jiujiang Gongqing City Industrial District 1 South Road Patentee before: JIUJIANG DACHENG PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address |